Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Taysha Gene Therapies, Inc. has initiated an underwritten public offering of up to $75 million in common stock and pre-funded warrants, subject to market conditions [1][2]. Company Overview - Taysha Gene Therapies is a clinical-stage biotechnology company focused on AAV-based gene therapies for severe monogenic diseases of the central nervous system [6]. - The company's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies [6]. - Taysha aims to address severe unmet medical needs and improve the lives of patients and caregivers through transformative medicines [6]. Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of the shares offered [1]. - Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, with Cantor also serving as a book-running manager [2].